Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics' Q1 Revenues up 75 Percent on Lingering Roche Revenue

NEW YORK (GenomeWeb News) — Epigenomics last week said first-quarter revenue increased 75 percent as R&D spending rose 31 percent and net loss decreased 15 percent.
Total receipts for the three months ended March 31, 2007, increased to €820,000 ($1.12 million) from €470,000 ($640,000) year over year.
Epigenomics said the revenue in part came from a collaboration with Roche Diagnostics, which officially ended on March 14, from several ongoing biomarker collaborations, and from a partnership with Centocor.
R&D spending increased to €2.5 million from €1.9 million year over year.
The company said its net loss was €3.4 million, compared with €4 million in the year-ago period.
Epigenomics said it had around €13.7 million in liquid assets as of March 31.
CEO Geert Nygaard said in a statement that Epigenomics’ blood-based colorectal cancer screening test and an improved assay procedure for detecting cancers will be the key drivers for future revenues, and that developing those programs will be the company’s main priority in 2007.
The company said it expects revenue of around €3.6 million for full year 2007.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.